In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...
Read More
In a nutshell This review aimed to explore the effectiveness and safety of gemtuzumab ozogamicin (GO; Mylotarg) in different subtypes of acute myeloid leukemia (AML). This review concluded that this treatment is safe and effective in certain patients with AML. Some background GO is an...
Read More
In a nutshell The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin...
Read More
In a nutshell This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients. Some...
Read More
In a nutshell This study investigated the change in central retinal thickness (CRT) by optical coherence tomography (OCT) in patients with type 2 diabetes (T2D) after 12 weeks of treatment with dapagliflozin (Farxiga) or glibenclamide (Diabeta). The authors concluded that CRT may improve with short-term use of dapagliflozin compared with...
Read More
In a nutshell This study investigated the effect of exenatide (EXE; Byetta) on kidney function, obesity and glucose control in overweight or obese patients with type 2 diabetes (T2D). The data showed that EXE could assist in improving kidney function, glucose control, and inflammation after 24 weeks of treatment. Some background Diabetic...
Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute myeloid leukemia. Fortunately, blood...
Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute leukemia. Fortunately, blood...
Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute leukemia. Fortunately, blood...
Read More
